Browse the corpus

The autonomic pharmacology program focuses on the sympathetic (SNS) and parasympathetic (PSNS) nervous systems, emphasizing their essential roles in regulating involuntary reactions across multiple organ systems. This activity explores how pathological conditions can disrupt the balance between the SNS and PSNS, leading to overactivity in one branch and inhibition in the other. These imbalances cause a range of clinical issues, from mild symptoms to severe outcomes such as cardiovascular collapse. This activity highlights the classification of drugs approved by the US Food and Drug Administration (FDA) within autonomic pharmacology, including cholinomimetics or cholinesterase antagonists, anticholinergics, adrenoreceptor agonists or sympathomimetics, and adrenoreceptor antagonists, which participants learn about in detail. This activity covers the indications, mechanisms of action, adverse effects, contraindications, toxicology, and monitoring required to use these drugs effectively. This activity enhances the understanding of interprofessional healthcare providers of the pharmacological effects of drugs impacting the autonomic nervous system by providing a detailed examination of the pharmacology related to autonomic drugs. This activity also prepares the healthcare team to collaborate effectively in administering these medications with greater precision and efficacy, thereby enhancing therapeutic outcomes and ensuring personalized patient care and optimized health outcomes. Objectives: Identify the roles of the sympathetic and parasympathetic nervous systems in regulating involuntary reactions across multiple organ systems. Implement appropriate therapeutic interventions using autonomic pharmacology drugs based on clinical indications. Select the most effective autonomic drug for specific clinical scenarios. Collaborate with interprofessional healthcare teams to optimize the use of autonomic pharmacology in patient care. Access free multiple choice questions on this topic.

Toxic profiles of the 4 categories described are primarily involved in overdose, exhibiting the same effects that are augmented so that the benefits no longer outweigh the risks. The primary reversal strategy for these situations is discontinuing the offending agent and treating the resultant symptoms.[1] Several agents of each category have toxic effects that require more specific reversal methods, as listed.[8][42][43][44] Cholinesterase inhibitors, including neostigmine, pyridostigmine, and physostigmine: Historically, high doses of these agents were used in chemical warfare and would present as miosis, bronchial constriction, vomiting, and diarrhea, progressing to convulsions, coma, and finally death. This toxicity profile remains the same and can be reversed with pralidoxime with adjunctive parenteral atropine and benzodiazepines for possible seizure activity. Atropine: In excess, atropine can cause vision disturbances, resulting in prolonged mydriasis and cycloplegia. This drug can also exacerbate closed-angle glaucoma by increasing intraocular pressure. Reversal generally involves discontinuation; however, physostigmine can be used in extreme cases, such as severe elevation of body temperature and rapid supraventricular tachycardia. Clonidine: Excessive clonidine use can lead to xerostomia and sedation. Currently, there is no approved reversal agent. However, studies are underway investigating the use of naloxone as a potential reversal agent. β-Blockers: In addition to severe hypotension and bradycardia, tremors and bronchospasm are worrisome in cases of overdose. Glucagon serves as the reversal agent in such situations.

Healthcare professionals prescribing medications affecting the autonomic system must fully understand the adverse effects of these agents. Physicians, nurses, and pharmacists should collaborate when utilizing medications that interact with the ANS to ensure safe and effective pharmacotherapy for each patient. ANS agents are used to treat conditions such as asthma, myasthenia gravis, nicotine replacement therapies, motion sickness, abdominal pain associated with irritable bowel syndrome, hypertension, hypotension, and Alzheimer disease. Clinicians are advised to conduct drug interaction checks when prescribing medications that influence the ANS for medical conditions. Nurses should verify dosage and ensure proper administration techniques are used for medications. Pharmacists are responsible for checking dosage, strength, and clinical appropriateness to minimize medication errors and educate patients about the drug’s adverse reactions. Medical toxicologists are essential for managing severe poisoning or overdose of ANS agents. In cases of deliberate overdose, psychiatric consultation is necessary. Clinicians, specialists, pharmacists, nurses, and other healthcare providers are critical in caring for patients undergoing therapy with ANS agents. Effective collaboration among all healthcare professionals within an interprofessional team enhances efficacy, reduces adverse reactions, and ultimately improves patient outcomes.